EP4061384A4 - Blood plasma fractions for use in liver regeneration - Google Patents

Blood plasma fractions for use in liver regeneration Download PDF

Info

Publication number: EP4061384A4
Authority: EP; European Patent Office
Prior art keywords: blood plasma; liver regeneration; plasma fractions; fractions; regeneration
Prior art date: 2019-11-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP20889920.3A

Other languages

German (de)

French (fr)

Other versions

EP4061384A1 (en

Inventor

Viktoria Kheifets

Benson LU

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alkahest Inc

Original Assignee

Alkahest Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-11-20

Filing date

2020-11-18

Publication date

2023-11-01

2020-11-18 Application filed by Alkahest Inc filed Critical Alkahest Inc

2022-09-28 Publication of EP4061384A1 publication Critical patent/EP4061384A1/en

2023-11-01 Publication of EP4061384A4 publication Critical patent/EP4061384A4/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Surgery (AREA)
Marine Sciences & Fisheries (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP20889920.3A 2019-11-20 2020-11-18 Blood plasma fractions for use in liver regeneration Pending EP4061384A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962937965P	2019-11-20	2019-11-20
US202062975637P	2020-02-12	2020-02-12
PCT/US2020/061098 WO2021102032A1 (en)	2019-11-20	2020-11-18	Blood plasma fractions for use in liver regeneration

Publications (2)

Publication Number	Publication Date
EP4061384A1 EP4061384A1 (en)	2022-09-28
EP4061384A4 true EP4061384A4 (en)	2023-11-01

Family

ID=75908417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP20889920.3A Pending EP4061384A4 (en)	2019-11-20	2020-11-18	Blood plasma fractions for use in liver regeneration

Country Status (8)

Country	Link
US (1)	US11660316B2 (en)
EP (1)	EP4061384A4 (en)
JP (1)	JP7754810B2 (en)
CN (2)	CN114746100B (en)
AU (1)	AU2020388572A1 (en)
CA (1)	CA3156906A1 (en)
TW (1)	TW202131935A (en)
WO (1)	WO2021102032A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11484551B2 (en) *	2019-11-20	2022-11-01	Alkahest, Inc.	Method of treating liver failure with plasma fraction IV-4
WO2022245552A1 (en) *	2021-05-19	2022-11-24	Alkahest, Inc.	Blood plasma fractions for use in liver regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170232118A1 (en) *	2013-12-09	2017-08-17	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening human blood products comprising plasma using immunocompromised rodent models
WO2018115953A1 (en) *	2016-12-21	2018-06-28	Prometic Pharma Smt Limited	Methods and compositions for preventing or minimizing epithelial-mesenchymal transition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3869431A (en)	1973-03-12	1975-03-04	Firestone Tire & Rubber Co	Polyamides and their production
US4624780A (en)	1982-06-28	1986-11-25	Alpha Therapeutic Corporation	Fractionation of blood plasma
US5110907A (en)	1989-08-01	1992-05-05	Alpha Therapeutic Corporation	Factor viii complex purification using heparin affinity chromatography
US5288853A (en)	1992-04-30	1994-02-22	Alpha Therapeutic Corporation	Factor viii purification process
US5219995A (en)	1992-07-14	1993-06-15	Alpha Therapeutic Corporation	Plasma fraction purification
JP2000106882A (en) *	1998-10-02	2000-04-18	Chemo Sero Therapeut Res Inst	Plasma protein fragment-producing enzyme having cancer metastasis growth inhibitory activity and plasma protein fragment fragmented by the enzyme
US6806355B2 (en) *	2001-08-14	2004-10-19	Statens Serum Institut	Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US20060292162A1 (en) *	2005-04-22	2006-12-28	Buckheit Robert W Jr	Plasma or serum fraction for the treatment or prevention of bacterial infections
ES2257225B1 (en)	2006-02-17	2007-03-16	Grifols, S.A	THERAPEUTIC PREPARATION OF FVIIA OF VERY HIGH PURITY AND METHOD FOR OBTAINING IT.
KR20070113876A (en) *	2006-05-26	2007-11-29	메디제네스(주)	Pharmaceutical composition for the treatment of wounds containing plasma components
ES2583371T3 (en) *	2006-10-11	2016-09-20	The General Hospital Corporation	Compositions, methods, and devices to treat liver diseases
WO2008133225A1 (en)	2007-04-23	2008-11-06	Nihon Pharmaceutical Co., Ltd.	Remedy for acute hepatitis or preventive/remedy for fulminant hepatitis
PT2271382E (en)	2008-04-15	2013-05-07	Grifols Therapeutics Inc	Two-stage ultrafiltration/diafiltration
RS20120461A1 (en)	2009-07-02	2013-06-28	Musc Foundation For Research Development	METHODS FOR STIMULATION OF LIVER REGENERATION
PT2673296T (en)	2011-02-07	2019-01-31	Cerenis Therapeutics Holding Sa	Lipoprotein complexes and manufacturing and uses thereof
JP6667438B2 (en)	2013-12-09	2020-03-18	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	Methods and compositions for treating conditions associated with aging
ES2524516B1 (en)	2014-05-29	2015-03-31	Grifols Worldwide Operations Limited	Preparation procedure of human albumin with reduced dissolved oxygen level
FR3040882A1 (en) *	2015-09-10	2017-03-17	Lab Francais Du Fractionnement	LIQUID COMPOSITION OF HUMAN ALBUMIN FOR THERAPEUTIC USE
CN105153297B (en)	2015-09-17	2020-03-31	中国人民解放军军事医学科学院野战输血研究所	Method for separating and purifying α 2-macroglobulin from Cohn component IV precipitate
ES2975517T3 (en)	2016-04-28	2024-07-08	Alkahest Inc	Plasma fractions as therapy for thymus cancer
SG11201901273TA (en)	2016-08-18	2019-03-28	Alkahest Inc	Blood plasma fractions as a treatment for aging-associated cognitive disorders
EA039316B1 (en)	2016-10-24	2022-01-12	Алкахест, Инк.	Blood plasma fractions as a treatment for aging-associated cognitive disorders
CN117899111A (en)	2017-04-26	2024-04-19	万能溶剂有限公司	Dosing regimen for treatment of cognitive and movement disorders with plasma and plasma preparations
US11040068B2 (en)	2017-04-26	2021-06-22	Alkahest, Inc.	Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
KR20210024196A (en)	2018-07-20	2021-03-04	알카헤스트 인코포레이티드	Dosage therapy for treatment of cognitive and motor disorders with plasma and plasma products
UA128648C2 (en)	2018-10-26	2024-09-18	Алкахест, Інк.	USE OF BLOOD PLASMA AND PLASMA FRACTIONS TO RELIEVE PAIN, IMPROVE WOUND HEALING AND POST-OPERATIVE RECOVERY
CA3151943A1 (en)	2019-11-04	2021-05-14	Viktoria Kheifets	Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) *	2019-11-20	2022-11-01	Alkahest, Inc.	Method of treating liver failure with plasma fraction IV-4

2020
- 2020-11-18 EP EP20889920.3A patent/EP4061384A4/en active Pending
- 2020-11-18 US US16/951,891 patent/US11660316B2/en active Active
- 2020-11-18 WO PCT/US2020/061098 patent/WO2021102032A1/en not_active Ceased
- 2020-11-18 CA CA3156906A patent/CA3156906A1/en active Pending
- 2020-11-18 CN CN202080080810.6A patent/CN114746100B/en active Active
- 2020-11-18 CN CN202411490437.8A patent/CN119215068A/en active Pending
- 2020-11-18 JP JP2022529741A patent/JP7754810B2/en active Active
- 2020-11-18 AU AU2020388572A patent/AU2020388572A1/en active Pending
- 2020-11-19 TW TW109140625A patent/TW202131935A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170232118A1 (en) *	2013-12-09	2017-08-17	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening human blood products comprising plasma using immunocompromised rodent models
WO2018115953A1 (en) *	2016-12-21	2018-06-28	Prometic Pharma Smt Limited	Methods and compositions for preventing or minimizing epithelial-mesenchymal transition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Acute liver failure - Symptoms and causes - Mayo Clinic", 29 October 2019 (2019-10-29), pages 1 - 6, XP093084499, Retrieved from the Internet <URL:https://web.archive.org/web/20191029124956/https://www.mayoclinic.org/diseases-conditions/acute-liver-failure/symptoms-causes/syc-20352863> [retrieved on 20230921] *
DE MATTOS �NGELO ZAMBAM ET AL: "Acute-on-chronic liver failure-old concepts made clearer", TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, vol. 2, no. 12, 18 December 2017 (2017-12-18), pages 111 - 111, XP093085028, DOI: 10.21037/tgh.2017.11.17 *
See also references of WO2021102032A1 *
TSUYOSHI KUROKAWA ET AL: "Effect of L-arginine supplement on liver regeneration after partial hepatectomy in rats", WORLD JOURNAL OF SURGICAL ONCOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 31 May 2012 (2012-05-31), pages 99, XP021116070, ISSN: 1477-7819, DOI: 10.1186/1477-7819-10-99 *

Also Published As

Publication number	Publication date
US20210145875A1 (en)	2021-05-20
CN119215068A (en)	2024-12-31
US11660316B2 (en)	2023-05-30
TW202131935A (en)	2021-09-01
CN114746100A (en)	2022-07-12
CA3156906A1 (en)	2021-05-27
WO2021102032A1 (en)	2021-05-27
JP2023502496A (en)	2023-01-24
AU2020388572A1 (en)	2022-05-26
CN114746100B (en)	2024-10-25
JP7754810B2 (en)	2025-10-15
EP4061384A1 (en)	2022-09-28

Legal Events

Date	Code	Title	Description
2021-05-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-08-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-08-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-09-28	17P	Request for examination filed	Effective date: 20220517
2022-09-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-03-01	RAV	Requested validation state of the european patent: fee paid	Extension state: MD Effective date: 20220524 Extension state: MA Effective date: 20220524
2023-05-12	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40081115 Country of ref document: HK
2023-09-28	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0035160000 Ipc: A61K0038380000
2023-11-01	A4	Supplementary search report drawn up and despatched	Effective date: 20231005
2023-11-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 41/00 20060101ALI20230928BHEP Ipc: A61P 1/16 20060101ALI20230928BHEP Ipc: A61K 35/16 20150101ALI20230928BHEP Ipc: A61K 38/38 20060101AFI20230928BHEP
2025-01-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-02-19	17Q	First examination report despatched	Effective date: 20250121
2026-03-04	P01	Opt-out of the competence of the unified patent court (upc) registered	Free format text: CASE NUMBER: UPC_APP_0002265_4061384/2026 Effective date: 20260121

Publication	Publication Date	Title
EP4054597A4 (en)	2024-02-21	Blood plasma fractions for use in muscle regeneration
EP3826645A4 (en)	2023-05-17	Compounds and methods for reducing atxn2 expression
EP3769654A4 (en)	2022-01-12	Cleaner holder and cleaner unit
AU2020285524A1 (en)	2020-12-03	Methods and user interfaces for sharing audio
EP3938514A4 (en)	2023-05-03	Compounds and methods for reducing kcnt1 expression
EP3206633A4 (en)	2018-07-18	Irrigation resistant compositions for regeneration of hard tissues and methods and kits of using the same
EP4051327A4 (en)	2023-11-22	3d-bioprinted scaffolds for tissue regeneration
CA3290013A1 (en)	2025-11-29	Techniques for dialysis based on relative blood volume
HK40081115A (en)	2023-05-12	Blood plasma fractions for use in liver regeneration
EP3826642B8 (en)	2025-06-11	Empagliflozin for use in treating alport syndrome
EP3941586A4 (en)	2023-03-15	Arginine gingipain inhibitors
EP3735167A4 (en)	2021-09-08	Mirror assembly for use in dentistry
HK40067656A (en)	2022-09-09	Potassium-binding agents for use in hemodialysis patients
HK40060353A (en)	2022-05-13	Methods for administering corticosteroids
HK40072912A (en)	2022-12-02	Anti-sortilin antibodies for use in therapy
HK40069789A (en)	2022-10-14	Indole compounds for use in neurorestoration
HK40074656A (en)	2023-01-06	Incretin analogs and uses thereof
HK40073823A (en)	2022-12-23	Methods for protein purification
HK40073793A (en)	2022-12-23	Ire1 activating compounds for use in therapy
HK40066915A (en)	2022-08-26	Compounds and methods for reducing kcnt1 expression
HK40109274A (en)	2024-11-29	Ppar-agonists for use in the treatment of liver failure
HK40071194A (en)	2022-11-04	Multispecific proteins
HK40065062A (en)	2022-07-15	Combination therapies for use in treating cancer
HK40101036A (en)	2024-05-10	Prefusion-stabilized hmpv f proteins
HK40056376A (en)	2022-03-25	Biovessels for use in tissue engineering